Abstract: The invention provides antibody-like binding proteins comprising four polypeptide chains that form four antigen binding sites, wherein each pair of polypeptides forming an antibody-like binding protein possesses dual variable domains having a cross-over orientation. The invention also provides methods for making such antigen-like binding proteins.

Abstract: The present invention relates to a device in the form of a suction nozzle (10) for an urban or industrial aspirator (1), preferably self-propelled, comprising a rigid hose or tube (1000), said rigid hose or tube comprising gripping means (100, 200, 300) that comprise a first gripping element (110, 210, 310) in the form of a handle, a support element (120, 220, 320) serving as a lever, and a second gripping element (130, 230, 330) and optionally a base (101, 201, 301).

Abstract: The present invention relates to a peptide or peptide complex binding to ?2 integrin, to one or more nucleic acid(s) coding for the peptide or peptide complex, a recombinant cell producing the peptide or peptide complex, a method for producing the peptide or peptide complex, a pharmaceutical composition comprising the peptide or peptide complex or the nucleic acid(s) for use as a medicament, a method for detecting ?2 integrin and a screening method.

Abstract: An assembly mount for the movable fastening of a motor vehicle assembly (such as an engine) having a housing which is connectable to a motor vehicle body, a fastening bolt which is connectable to the motor vehicle assembly and which projects into the housing via a housing opening, a load-bearing spring which is connected to the housing and to the fastening bolt, wherein the load-bearing spring permits at least a relative movement of the fastening bolt in an opening plane of the housing opening within the housing opening, and a compensation element which is movable relative to the housing and relative to the fastening bolt and which serves for the variation of a movement clearance of the fastening bolt in the housing opening in the opening plane.

Abstract: The present invention relates to a peptide or peptide complex binding to ?2 integrin, to one or more nucleic acid(s) coding for the peptide or peptide complex, a recombinant cell producing the peptide or peptide complex, a method for producing the peptide or peptide complex, a pharmaceutical composition comprising the peptide or peptide complex or the nucleic acid(s) for use as a medicament, a method for detecting ?2 integrin and a screening method.

Abstract: The invention provides antibody-like binding proteins comprising four polypeptide chains that form four antigen binding sites, wherein each pair of polypeptides forming an antibody-like binding protein possesses dual variable domains having a cross-over orientation. The invention also provides methods for making such antigen-like binding proteins.

Abstract: The invention provides antibody-like binding proteins comprising four polypeptide chains that form four antigen binding sites, wherein each pair of polypeptides forming an antibody-like binding protein possesses dual variable domains having a cross-over orientation. The invention also provides methods for making such antigen-like binding proteins.

Abstract: An exemplary method and apparatus are provided for improved control for induction coils in charging systems for movable vehicles. The technique includes determining a set point for a second induction coil from information about a power transfer of a first induction coil. A switching time for operating the first induction coil in a first pre-determined operating mode is triggered based on a first set point, and a switching time for operating the second induction coil in a second pre-determined operating mode is triggered based on a second set point. The second set point may be determined based on the first set point and an offset.

Abstract: The invention relates to a connecting structure between building blocks and to a building block. The connecting structure according to the invention has a relatively simple structural design so as to be easily producible and releasable. Furthermore the connecting structure allows a quick modification of the orientation of the building blocks relative to one another. In the process an energy and/or information transmission is allowed between the building blocks at the same time.

Abstract: The present invention relates to fusion proteins in which a biologically active moiety is linked to a targeting domain. The invention specifically concerns fusion proteins comprising single-chain (sc) TNFalpha monomers as biologically active moiety and a specific targeting domain, preferably fusion proteins comprising at least three scTNFalpha monomers and modified hetero-dimeric ubiquitin proteins with high affinity to target molecules (Affilin® molecules). The invention further relates to these fusion proteins for use in medicine, in particular in the treatment of cancer. The invention is further directed to pharmaceutical compositions comprising such fusion proteins in combination with chemotherapeutics agents.

Abstract: In a method, device and storage medium encoded with programming instructions for automatic image registration of image data of a current medical image MR study and at least one reference study, corresponding image pairs of the current study and the reference study are formed automatically with an association machine without needing the analyze the respective image data or pixel data. The pair determination takes place exclusively on the basis of the DICOM header data. A synchronized image processing and/or presentation of the generated image pairs takes place at a monitor.

Abstract: The present invention discloses novel antibodies that specifically bind to the human platelet membrane protein Glycoprotein VI (GPVI) and their monovalent fragments or derivatives. The antibodies of the invention are antibodies from hybridoma clone 390 and fragment antibodies thereof able to induce a GPVI depletion phenotype. These antibodies and Fab fragments are able to block collagen binding and thus preventing platelet activation by collagen. The invention also relates to hybridoma clones and expression plasmids for the production of disclosed antibodies and Fab fragments. The present invention further refers to the uses of monovalent antibody fragments to manufacture research, diagnostic and immunotherapeutic agents for the treatment of thrombosis and other vascular diseases. The invention also concerns a Fab bearing a molecule at the C-terminal extremity, as well as method for prevention of recognition of Fab by antibodies using such modified Fab.

Abstract: A modified L-nucleic acid, containing an L-nucleic acid part conjugated to a non-L-nucleic acid part is described. The conjugate has extended retention time in and demonstrates a delayed elimination from an organism.

Abstract: The present invention discloses novel antibodies that specifically bind to the human platelet membrane protein Glycoprotein VI (GPVI) and their monovalent fragments or derivatives. The antibodies of the invention are antibodies from hybridoma clone 390 and fragment antibodies thereof able to induce a GPVI depletion phenotype. These antibodies and Fab fragments are able to block collagen binding and thus preventing platelet activation by collagen. The invention also relates to hybridoma clones and expression plasmids for the production of disclosed antibodies and Fab fragments. The present invention further refers to the uses of monovalent antibody fragments to manufacture research, diagnostic and immunotherapeutic agents for the treatment of thrombosis and other vascular diseases. The invention also concerns a Fab bearing a molecule at the C-terminal extremity, as well as method for prevention of recognition of Fab by antibodies using such modified Fab.

Abstract: The invention relates to a companion diagnostic antibody-like binding protein based on the humanized monoclonal antibody, DS6, to be used as diagnostic tool for in vivo detection and quantification of the tumor-associated MUC1-sialoglycotope, CA6.

Abstract: The invention relates to a companion diagnostic antibody-like binding protein based on the humanized monoclonal antibody, DS6, to be used as diagnostic tool for in vivo detection and quantification of the tumor-associated MUC1-sialoglycotope, CA6.

Abstract: The present invention relates to fusion proteins in which a pharmaceutically active component is fused to an antibody mimetic. The invention specifically concerns fusion proteins comprising interferons or biologically active muteins thereof and modified hetero-dimeric ubiquitin proteins as specific targeting domain. The invention further relates to these fusion proteins for use in medicine, in particular for use in the treatment of cancer or infectious diseases. The invention is further directed to pharmaceutical compositions comprising a pharmaceutically acceptable carrier in combination with such fusion proteins, and in combination with cancer therapeutic agents. Moreover, the invention relates to a method for the generation of said fusion proteins.

Abstract: The invention provides antibody-like binding proteins comprising four polypeptide chains that form four antigen binding sites, wherein each pair of polypeptides forming an antibody-like binding protein possesses dual variable domains having a cross-over orientation. The invention also provides methods for making such antigen-like binding proteins.

Abstract: The invention provides antibody-like binding proteins comprising four polypeptide chains that form four antigen binding sites, wherein each pair of polypeptides forming an antibody-like binding protein possesses dual variable domains having a cross-over orientation. The invention also provides methods for making such antigen-like binding proteins.

Abstract: The invention provides antibody-like binding proteins comprising four polypeptide chains that form four antigen binding sites, wherein each pair of polypeptides forming an antibody-like binding protein possesses dual variable domains having a cross-over orientation. The invention also provides methods for making such antigen-like binding proteins.